Vol. 22 No. 3 (2018)
CORONARY ARTERY DISEASES

Results of stenting the left main lesions in patients with stable coronary artery disease using biodegradable polymer and permanent polymer stents

PDF (Русский)
  • R. Ibragimov,
  • A. Badoyan,
  • D. Khelimskiy,
  • O. Krestyaninov,
  • E. Pokushalov,
  • A. Romanov
R. Ibragimov
Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
Bio
A. Badoyan
Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
D. Khelimskiy
Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
O. Krestyaninov
Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
E. Pokushalov
Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
A. Romanov
Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2018-3-49-55

Published 2018-11-20

Keywords

  • Synergy,
  • Xience,
  • biodegradable polymer,
  • drug-eluting stent

How to Cite

Ibragimov, R., Badoyan, A., Khelimskiy, D., Krestyaninov, O., Pokushalov, E., & Romanov, A. (2018). Results of stenting the left main lesions in patients with stable coronary artery disease using biodegradable polymer and permanent polymer stents. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 22(3), 49–55. https://doi.org/10.21688/1681-3472-2018-3-49-55

Copyright (c) 2018 Ibragimov R. U., Badoyan A. G., Khelimskiy D. A., Krestyaninov O. V., Pokushalov E. A., Romanov A. B.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background. Routine coronary angiography reveals about 4–10% cases of the left main lesions in patients with different forms of coronary artery disease. With the advance of stenting technologies, percutaneous coronary intervention in this type of lesions might be an alternative to coronary artery bypass grafting in some patients. Despite a significant technical progress and current generations of drug-eluting stents, the issue of optimal dual antiplatelet therapy (DAAT) duration to minimize hemorrhagic complications in the long-term period is still an open question. The problem is especially acute in the case of left main lesions.
Aim. To evaluate clinical outcomes of unprotected left main stenting using Synergy stents (Boston Scientific) followed by 4-month DAAT and Xience Prime stents (Abbott Vascular) followed by 12-month DAAT.
Methods. Fifty patients with stable coronary artery disease were randomized into two groups depending on the stent type (Synergy and Xience). The subjects were evaluated in 12 months after the stenting procedure.
Results. 100 % success was achieved in the study. At 3-month check-up, the indicators of endothelialization, strut overlapping and late lumen bore did not statistically differ in the groups under study. During 12-month follow-up 2 cases of restenosis were recorded, one in each group, which required revascularization. The remaining cases of repeated revascularization were associated with de novo lesions. The overall major cardiac events rate was 4% in the Xience group and 8% in the Synergy group. In one case, myocardial infarction in the Synergy group was associated with the right coronary artery.
Conclusion. While treating patients with left main lesions, the use of Synergy stents followed by 4-month DAAT has no lesser clinical efficacy and safety than the Xience stents followed by 12-month DAAT.

Received 28 August 2018. Revised 8 October 2017. Accepted 8 November 2018.

Funding: The study did not have sponsorship.

Conflict of interest: Authors declare no conflict of interest.

Author contributions
Conception and study design: R.U. Ibragimov, O.V. Krestyaninov
Data collection and analysis: R.U. Ibragimov, D.A. Khelimskiy, A.G. Badoyan
Statistical analysis: R.U. Ibragimov, D.A. Khelimskiy, A.G. Badoyan
Drafting the article: R.U. Ibragimov, D.A. Khelimskiy, A.G. Badoyan
Revision of the article: R.U. Ibragimov, O.V. Krestyaninov, E.A. Pokushalov, A.B. Romanov
Final approval of the version to be published: R.U. Ibragimov, A.G. Badoyan, D.A. Khelimskiy, O.V. Krestyaninov, E.A. Pokushalov, A.B. Romanov

ORCID ID
E.A. Pokushalov, https://orcid.org/0000-0002-2560-5167

PDF (Русский)

References

  1. Акбашева М.Т., Закарян Н.В., Алекян Б.Г. Современные подходы к рентгеноэндоваскулярному лечению при поражении «незащищенного» ствола левой коронарной артерии у пациентов с ишемической болезнью сердца. Креативная кардиология. 2009;(2):68-79. [Akbasheva M.T., Zakarian N.V., Alekian B.G. Modern approaches to endovascular treatment of unprotected left main disease in patients with coronary artery disease. Creative Cardiology. 2009;(2):68-79. (In Russ.)]
  2. Dacosta A., Tardy В., Favre J., Guy J.M., Rachet F., Lamaud M., Barral X., Verneyre H. Left main coronary artery disease. Arch Mal Coeur Vaiss. 1994;87(9);1225-32. (In Fr.) PMID: 7646237.
  3. Park S.J., Park S.W., Hong M., Lee C.W., Lee J.H., Kim J.J., Jang Y.S., Shin E.K., Yoshida Y., Tamura T., Kimura T., Nobuyoshi M. Long-term (three-year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Am J Cardiol. 2003;91(1):12-6. PMID: 12505564.
  4. Chieffo A., Stankovic G., Bonizzoni E., Tsagalou E., Iakovou I., Montorfano M., Airoldi F., Michev I., Sangiorgi M.G., Carlino M., Vitrella G., Colombo A. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation. 2005;111(6):791-5. PMID: 1569925. http://dx.doi.org/10.1161/01.CIR.0000155256.88940.F8
  5. Silvestri M., Baragan P., Sainsous J., Bayet G., Simeoni J.B., Roquebert P.O., Macaluso G., Bouvier J.L., Comet B. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol. 2000;35(6):1543-50. PMID: 10807458
  6. Tan W.A., Tamai H., Park S.J., Plokker H.W., Nobuyoshi M., Suzuki T., Colombo A., Macaya C., Holmes D.R. Jr., Cohen D.J., Whitlow P.L., Ellis S.G.; ULTIMA Investigators. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation. 2001;104(14):1609-14. PMID: 11581137.
  7. Ибрагимов Р.У., Бадоян А.Г., Крестьянинов О.В., Покушалов Е.А., Нарышкин И.А., Кретов Е.И., Прхорихин А.А., Хелимский Д.А. Сравнительный анализ эндотелиального покрытия эверолимус-выделяющих стентов Synergy с биодеградируемым покрытием и Xience с постоянным полимером с помощью оптической когерентной томографии через 3 месяца после чрескожного коронарного вмешательства на стволе левой коронарной артерии. Патология кровообращения и кардиохирургия. 2017;21(4):59-68. http://dx.doi.org/10.21688/1681-3472-2017-4-59-68 [Ibragimov R.U., Badoyan A.G., Krestyaninov O.V., Pokushalov E.A., Naryshkin I.A., Kretov E.I., Prokhorikhin A.A., Khelimskiy D.A. Optical coherence tomography for evaluating Synergy everolimus-eluting stents with biodegradable polymer and Xience durable polymer everolimus-eluting stents following percutaneous coronary intervention in patients with left main coronary artery stenosis. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2017;21(4):59-68. (In Russ.). http://dx.doi.org/10.21688/1681-3472-2017-4-59-68]
  8. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., Dudek D., Fort S., Schiele F., Zmudka K., Guagliumi G., Russell M.E.; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;19(108):788-94. PMID: 12900339. http://dx.doi.org/10.1161/01.CIR.0000086926.62288.A6
  9. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E.; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-23. PMID: 14523139. http://dx.doi.org/10.1056/NEJMoa035071
  10. Armstrong E.J., Feldman D.N., Wang T.Y., Kaltenbach L.A., Yeo K.K., Wong S.C., Spertus J., Shaw R.E., Minutello R.M., Moussa I., Ho K.K., Rogers J.H., Shunk K.A. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5(2):131-140. PMID: 22361596. http://dx.doi.org/10.1016/j.jcin.2011.10.013
  11. Schulz S., Schuster T., Mehilli J., Byrne R.A., Ellert J., Massberg S., Goedel J., Bruskina O., Ulm K., Schömig A., Kastrati A. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714-21. PMID: 19596658. http://dx.doi.org/10.1093/eurheartj/ehp275
  12. Holmes D.R. Jr., Kereiakes D.J., Garg S., Serruys P.W., Dehmer G.J., Ellis S.G., Williams D.O., Kimura T., Moliterno D.J. Stent thrombosis. J Am Coll Cardiol. 2010;56(17):1357-65. PMID: 20946992. http://dx.doi.org/10.1016/j.jacc.2010.07.016
  13. Nakazawa G., Finn A.V., Joner M., Ladich E., Kutys R., Mont E.K., Gold H.K., Burke A.P., Kolodgie F.D., Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118(11):1138-45. PMID: 18725485. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.762047
  14. Kotani J., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., Mintz G.S., Nagata S. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47(10):2108-11. PMID: 16697331. http://dx.doi.org/10.1016/j.jacc.2005.11.092
  15. Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C., Gold H.K., Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435-41.PMID: 17438147 http://dx.doi.org/10.1161/CIRCULATIONAHA.107.693739
  16. Kolh P., Windecker S., Alfonso F., Collet J.P., Cremer J., Falk V., Filippatos G., Hamm C., Head S.J., Jüni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G., Neumann F.J., Richter D.J., Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W., Witkowski A.; European Society of Cardiology Committee for Practice Guidelines, Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol Ç., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S.; EACTS Clinical Guidelines Committee, Sousa Uva M., Achenbach S., Pepper J., Anyanwu A., Badimon L., Bauersachs J., Baumbach A., Beygui F., Bonaros N., De Carlo M., Deaton C., Dobrev D., Dunning J., Eeckhout E., Gielen S., Hasdai D., Kirchhof P., Luckraz H., Mahrholdt H., Montalescot G., Paparella D., Rastan A.J., Sanmartin M., Sergeant P., Silber S., Tamargo J., ten Berg J., Thiele H., van Geuns R.J., Wagner H.O., Wassmann S., Wendler O., Zamorano J.L.; Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-92. PMID: 25173601. http://dx.doi.org/10.1093/ejcts/ezu366
  17. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., Chambers C.E., Ellis S.G., Guyton R.A., Hollenberg S.M., Khot U.N., Lange R.A., Mauri L., Mehran R., Moussa I.D., Mukherjee D., Nallamothu B.K., Ting H.H. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574-651. PMID: 22064601. http://dx.doi.org/10.1161/CIR.0b013e31823ba622
  18. Berger P.B., Bhatt D.L., Fuster V., Steg P.G., Fox K.A., Shao M., Brennan D.M., Hacke W., Montalescot G., Steinhubl S.R., Topol E.J.; CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121(23):2575-83. PMID: 20516378. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.895342
  19. Bowry A.D., Brookhart M.A., Choudhry N.K. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol. 2008;101(7):960-6. PMID: 18359315. http://dx.doi.org/10.1016/j.amjcard.2007.11.057
  20. Doyle B.J., Rihal C.S., Gastineau D.A., Holmes D.R. Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009;53(22):2019-27. PMID: 19477350. http://dx.doi.org/10.1016/j.jacc.2008.12.073
  21. Natsuaki M., Morimoto T., Yamamoto E., Shiomi H., Furukawa Y., Abe M., Nakao K., Ishikawa T., Kawai K., Yunoki K., Shimizu S., Akao M., Miki S., Yamamoto M., Okada H., Hoshino K., Kadota K., Morino Y., Igarashi K., Tanabe K., Kozuma K., Kimura T. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovascular Intervention and Therapeutics. 2016;31(3):196-209. PMID: 26518420, PMCID: PMC4923071. http://dx.doi.org/10.1007/s12928-015-0366-9
  22. Feres F., Costa R.A., Abizaid A., Leon M.B., Marin-Neto J.A., Botelho R.V., King S.B. 3rd, Negoita M., Liu M., de Paula J.E., Mangione J.A., Meireles G.X., Castello H.J. Jr., Nicolela E.L. Jr., Perin M.A., Devito F.S., Labrunie A., Salvadori D. Jr., Gusmão M., Staico R., Costa J.R. Jr., de Castro J.P., Abizaid A.S., Bhatt D.L.; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510-22. PMID: 24177257. http://dx.doi.org/10.1001/jama.2013.282183
  23. Kim B.K., Hong M.K., Shin D.H., Nam C.M., Kim J.S., Ko Y.G., Choi D., Kang T.S., Park B.E., Kang W.C., Lee S.H., Yoon J.H., Hong B.K., Kwon H.M., Jang Y.; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340-8. PMID: 22999717. http://dx.doi.org/10.1016/j.jacc.2012.06.043
  24. Palmerini T., Della Riva D., Benedetto U., Bacchi Reggiani L., Feres F., Abizaid A., Gilard M., Morice M.C., Valgimigli M., Hong M.K., Kim B.K., Jang Y., Kim H.S., Park K.W., Colombo A., Chieffo A., Sangiorgi D., Biondi-Zoccai G., Généreux P., Angelini G.D., Pufulete M., White J., Bhatt D.L., Stone G.W. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017;38(14):1034-1043. PMID: 28110296, PMCID: PMC5837418. http://dx.doi.org/10.1093/eurheartj/ehw627.
  25. Varenne O., Cook S., Sideris G., Kedev S., Cuisset T., Carrié D., Hovasse T., Garot P., El Mahmoud R., Spaulding C., Helft G., Diaz Fernandez J.F., Brugaletta S., Pinar-Bermudez E., Mauri Ferre J., Commeau P., Teiger E., Bogaerts K., Sabate M., Morice M.C., Sinnaeve P.R.; SENIOR investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41-50. PMID: 29102362. http://dx.doi.org/10.1016/S0140-6736(17)32713-7